Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 3 March 2025, 14:41 HKT/SGT
Share:
    

Source: Eisai
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
- Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and Glycine -

TOKYO, Mar 3, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today the launch of the new nutritional drink “Chocola BB® Nightwell” (designated quasi-drug product), a nutritional drink to help recovery from the accumulated fatigue of the day during sleep, on Monday, March 3. The productbelongs to the Chocola BB brand, which supports people’s beauty and health, and will be available at pharmacy and drugstores throughout Japan.

Chocola BB Nightwell contains eight active ingredients, including vitamin B2, which supports fatmetabolism and converts it into energy, and glycine, which improves sleep quality associated with poornutrition, as well as herbal medicines (Crataegus oxyacantha and Citrus unshiu peel). With a grapefruit flavor, Chocola BB Nightwell is easy to drink, low in calories (5.1 kcal per bottle), and caffeine-free, allowing consumption before bedtime. By promoting fatigue recovery during sleep, Chocola BB Nightwell supports a refreshed start to the day.

Since the launch of Chocola BB tablets in 1952, the Chocola BB brand has been offering products forover 70 years to address various skin and fatigue symptoms, in line with the needs of each era. The current Chocola BB drink lineup consists of designated quasi-drugs for fatigue care, including “ChocolaBB® Light” for daily fatigue, “Chocola BB® Royal 2” for severe fatigue, and “Chocola BB® Hyper” for low vitality.

By marketing the Chocola BB series of products, Eisai is committed to addressing the diverse needswithin fatigue care, and supporting the beauty and wellness of even more people.

Please refer to the product’s website for details about Chocola BB Nightwell (Japanese only) www.eisai.jp/products/chocola/chocola_bb_nightwell

FOr more information, visit https://www.eisai.com/news/2025/news202514.html

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Mar 23, 2026 10:19 HKT/SGT
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
Mar 19, 2026 09:54 HKT/SGT
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
Mar 17, 2026 18:49 HKT/SGT
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
Mar 12, 2026 16:21 HKT/SGT
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
Mar 11, 2026 11:07 HKT/SGT
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
Mar 2, 2026 08:49 HKT/SGT
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Feb 16, 2026 13:03 HKT/SGT
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
Feb 10, 2026 12:34 HKT/SGT
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Feb 6, 2026 10:31 HKT/SGT
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
Jan 26, 2026 10:37 HKT/SGT
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
More news >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: